Next Article in Journal
Antibody–Drug Conjugates for Cancer Therapy
Next Article in Special Issue
Fifty Years of Clinical Application of Newcastle Disease Virus: Time to Celebrate!
Previous Article in Journal
Plant Toxin-Based Immunotoxins for Cancer Therapy: A Short Overview
Previous Article in Special Issue
In Vitro Synergistic Enhancement of Newcastle Disease Virus to 5-Fluorouracil Cytotoxicity against Tumor Cells
Article Menu

Export Article

Open AccessFeature PaperReview
Biomedicines 2016, 4(3), 13; doi:10.3390/biomedicines4030013

Tumor-Associated Macrophages in Oncolytic Virotherapy: Friend or Foe?

Center for Childhood Cancer and Blood Diseases, Division of Hematology/Oncology/Blood and Marrow Transplant, Nationwide Children’s Hospital, The Ohio State University, Columbus, OH 43205, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Zong Sheng Guo
Received: 21 May 2016 / Revised: 28 June 2016 / Accepted: 4 July 2016 / Published: 7 July 2016
(This article belongs to the Special Issue Oncolytic Viruses as a Novel Form of Immunotherapy for Cancer)
View Full-Text   |   Download PDF [413 KB, uploaded 7 July 2016]   |  

Abstract

Cancer therapy remains a challenge due to toxicity limitations of chemotherapy and radiation therapy. Oncolytic viruses that selectively replicate and destroy cancer cells are of increasing interest. In addition to direct cell lysis, these vectors stimulate an anti-tumor immune response. A key regulator of tumor immunity is the tumor-associated macrophage population. Macrophages can either support oncolytic virus therapy through pro-inflammatory stimulation of the anti-tumor response at the cost of hindering direct oncolysis or through immunosuppressive protection of virus replication at the cost of hindering the anti-tumor immune response. Despite similarities in macrophage interaction between adult and pediatric tumors and the abundance of research supporting macrophage modulation in adult tumors, there are few studies investigating macrophage modulation in pediatric cancers or modulation of immunotherapy. We review the current state of knowledge regarding macrophages in cancers and their influence on oncolytic virotherapy. View Full-Text
Keywords: oncolytic virus; macrophage; carcinoma; neuroblastoma; sarcoma oncolytic virus; macrophage; carcinoma; neuroblastoma; sarcoma
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Denton, N.L.; Chen, C.-Y.; Scott, T.R.; Cripe, T.P. Tumor-Associated Macrophages in Oncolytic Virotherapy: Friend or Foe? Biomedicines 2016, 4, 13.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Biomedicines EISSN 2227-9059 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top